Theratechnologies (THTX)
(Delayed Data from NSDQ)
$1.23 USD
-0.03 (-2.38%)
Updated May 15, 2024 10:05 AM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Income Statements
Fiscal Year end for Theratechnologies Inc falls in the month of November .
All items in Millions except EPS data.
11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 | |
---|---|---|---|---|---|
Sales | 82 | 80 | 70 | 66 | 63 |
Cost Of Goods | 20 | 26 | 23 | 27 | 26 |
Gross Profit | 62 | 54 | 47 | 39 | 37 |
Selling & Adminstrative & Depr. & Amort Expenses | 73 | 94 | 72 | 57 | 46 |
Income After Depreciation & Amortization | -11 | -40 | -25 | -18 | -9 |
Non-Operating Income | 2 | 1 | 0 | 0 | 1 |
Interest Expense | 15 | 8 | 7 | 5 | 5 |
Pretax Income | -24 | -47 | -32 | -23 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -24 | -47 | -32 | -23 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -24 | -47 | -32 | -23 | -13 |
Depreciation Footnote | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -27 | -16 | -9 | -1 |
Depreciation & Amortization (Cash Flow) | 3 | 12 | 9 | 9 | 8 |
Income After Depreciation & Amortization | -11 | -40 | -25 | -18 | -9 |
Earnings Per Share Data | 11/30/23 | 11/30/22 | 11/30/21 | 11/30/20 | 11/30/19 |
---|---|---|---|---|---|
Average Shares | 26.33 | 23.81 | 23.09 | 18.89 | 19.23 |
Diluted EPS Before Non-Recurring Items | -0.91 | -2.00 | -1.36 | -1.20 | -0.56 |
Diluted Net EPS (GAAP) | -0.91 | -2.00 | -1.36 | -1.16 | -0.64 |
Fiscal Year end for Theratechnologies Inc falls in the month of November .
All items in Millions except EPS data.
2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 | |
---|---|---|---|---|---|
Sales | 16.25 | 23.45 | 20.86 | 17.55 | 19.91 |
Cost Of Goods | 5.28 | 5.07 | 4.97 | 4.91 | 4.69 |
Gross Profit | 10.96 | 18.39 | 15.89 | 12.64 | 15.22 |
SG&A, R&D, and Dept/Amort Expenses | 13.21 | 15.72 | 15.84 | 20.59 | 20.63 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.25 | 2.67 | 0.05 | -7.95 | -5.41 |
Non-Operating Income | 0.63 | -0.85 | 2.11 | 0.55 | 0.35 |
Interest Expense | 2.75 | 4.50 | 2.78 | 2.49 | 5.29 |
Pretax Income | -4.37 | -2.68 | -0.62 | -9.89 | -10.35 |
Income Taxes | 0.11 | 0.07 | 0.13 | 0.13 | 0.10 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.48 | -2.75 | -0.75 | -10.01 | -10.44 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.48 | -2.76 | -0.75 | -10.01 | -10.44 |
Earnings Per Share Data | 2/29/24 | 11/30/23 | 8/31/23 | 5/31/23 | 2/28/23 |
---|---|---|---|---|---|
Average Shares | 49.36 | 34.43 | 24.20 | 24.20 | 24.20 |
Diluted EPS Before Non-Recurring Items | -0.10 | -0.08 | -0.03 | -0.40 | -0.44 |
Diluted Net EPS (GAAP) | -0.10 | -0.04 | -0.03 | -0.40 | -0.44 |